Soluble activin receptor type IIB increases forward pulling tension in the mdx mouse

Muscle and Nerve

Volumn 43, Issue 5, 2011, Pages 694-699

  Carlson, C George ^a   Bruemmer, Kay ^a   Sesti, Jenna ^a   Stefanski, C ^a   Curtis, Heather ^a   Ucran, Jeffrey ^b   Lachey, Jennifer ^b   Seehra, Jasbir S ^b  

^a A T STILL UNIVERSITY   (United States)

^b Acceleron Pharma   (United States)

Author keywords

Activin receptor type IIB; Duchenne muscular dystrophy; Mdxmouse; Ursodeoxycholic acid; Whole body tension

Indexed keywords

ACTIVIN; ACTIVIN RECEPTOR 2; MYOSTATIN; RAP 031; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY BUILD; BODY CONSTITUTION; BODY DENSITY; BODY MASS; CONTROLLED STUDY; FEMALE; MALE; MOUSE; MUSCLE FUNCTION; MUSCLE MASS; MUSCLE STRENGTH; MUSCLE TONE; MUSCULAR DYSTROPHY; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ACTIVIN RECEPTORS, TYPE II; ANIMALS; FEMALE; MALE; MICE; MICE, INBRED MDX; MUSCLE CONTRACTION; MUSCLE TONUS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; SOLUBILITY;

EID: 79955555477     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21944     Document Type: Article

References (21)

1. Carlson CG, Makiejus RV. A non-invasive procedure to detect muscle weakness in the mdx mouse. Muscle Nerve 1990;3:480-484.
2. Makiejus RV, Patel VK, Krishna G, Dierdorf SF, Bonsett C. Effect of adenylosuccinate on the strength of dystrophin lacking muscles of mdx mice. Biochem Arch 1991;7:95-103.
3. Hudecki MS, Pollina CM, Granchelli JA, Daly MK, Byrnes T, Wang JC, et al. Strength and endurance in the therapeutic evaluation of prednisolone-treated mdx mice. Res Commun Chem Pathol Pharmacol 1993;79:45-60.
4. Deconinck N, Tinsley J, De Backer F, Fisher R, Kahn D, Phelps S, et al. Expression of truncated utrophin leads to major functional improvements in dystrophin deficient muscles of mice. Nat Med 1997;11:1216-1221.
5. Fougerousse, F, Gonin, P, Durand, M, Richard, I, Raymackers JM. Force impairment in calpain 3-deficient mice is not correlated with mechanical disruption. Muscle Nerve 2003;27:616-623.
6. Gillis JP. Multivariate evaluation of the functional recovery obtained by the overexpression of utrophin in skeletal muscles of the mdx mouse. Neuromuscul Disord 2002;12(suppl):S90-S94.
7. Squire S, Raymackers JM, Vandebrouk C, Potter A, Tinsley J, Fisher R, et al. Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression system. Hum Mol Genet 2002;11:3333-3344.
8. Raymackers JM, Debaix H, Colson-Van Schoor M, De Backer F, Tajeddine N, Schwaller B, et al. Consequence of parvalbumin deficiency in the mdx mouse: histological, biochemical and mechanical phenotype of a new double mutant. Neuromuscul Disord 2003;13: 376-387.
9. Siegel AL, Bledsoe C, Lavin J, Gatti F, Berge J, Millman G, et al. Treatment with inhibitors of the NF-kappaB pathway improves whole body tension development in the mdx mouse. Neuromuscul Disord 2009;19:131-139.
10. Carlson CG, Rutter J, Bledsoe C, Singh R, Hoff H, Bruemmer K, et al. A simple protocol for assessing inter-trial and inter-examiner reliability for two noninvasive measures of limb muscle strength. J Neurosci Methods 2010;186:226-230.
11. Carlson CG. Whole body tension measurements. SOP number M.2.2_006. http://www.treat-nmd.eu/research/preclinical/SOPs/;2009.
12. Bogdanovich S, Krag TOB, Barton ER, Morris LD, Whittemore L-A, Ahima RS, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002;420:418-421.
13. Qiao C, Jianbin L, Jiang J, Zhu X, Wang B, Li J, et al. Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice. Hum Gene Ther 2008;19:241-253.
14. Carlson CG, Samadi A, Siegel A. Chronic treatment with agents that stabilize cytosolic IjB-a enhances survival and improves resting membrane potential in mdx muscle fibers subjected to chronic passive stretch. Neurobiol Dis 2005;20:719-730.
15. Messina S, Bitto A, Aguennouz M, Minutoli L, Monici MC, Altavilla D, et al. Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice. Exp Neurol 2006;198:234-241.
16. κB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest 2007;117:889-901.
17. Hnia V, Hugon G, Rivier V, Masmoudi V, Mercier V, Mornet V. Modulation of p38 mitogen-activated protein kinase cascade and metalloproteinase activity in diaphragm muscle in response to free radical scavenger administration in dystrophin-deficient mdx mice. Am J Pathol 2007;170:633-643.
18. Whitehead NP, Pham C, Gervasio OL, Allen DG. N-Acetylcysteine ameliorates skeletal muscle pathophysiology in mdx mice. J Physiol (Lond) 2008;586:2003-2014.
19. Gillis JP. The recovery score to evaluate therapy efficiency in NMD: a common, quantitative, and comparative scoring system. SOP number M.1.1_001. http://www.treat-nmd.eu/research/preclinical/SOPs/;2008.
20. Morrison BM, Lachey JL, Warsing LC, Ting BL, Pullen AE, Underwood KW, et al. A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis. Exp Neurol 2009;217:258-268.
21. Miles MT, Carlson CG. Acute inhibition of NFjB with pyrrolidine dithiocarbamate (PDTC) improves the resting membrane potential of the triangularis sterni (TS) muscle in the dystrophic (mdx) mouse. Neurosci Abstr 2007;167.5.